Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 1.14.11.2 - procollagen-proline 4-dioxygenase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acute Kidney Injury
Role of Endothelial Prolyl-4-Hydroxylase Domain Protein/Hypoxia-Inducible Factor Axis in Acute Kidney Injury.
Adenocarcinoma
P4HA1/HIF1? feedback loop drives the glycolytic and malignant phenotypes of pancreatic cancer.
Adenocarcinoma of Lung
Collagen modifying enzyme P4HA1 is overexpressed and plays a role in lung adenocarcinoma.
Overexpression of P4HA1 Is Correlated with Poor Survival and Immune Infiltrates in Lung Adenocarcinoma.
Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors.
Alzheimer Disease
HIF prolyl hydroxylase inhibitors prevent neuronal death induced by mitochondrial toxins: therapeutic implications for Huntington's disease and Alzheimer's disease.
Anemia
1,3,8-Triazaspiro[4.5]decane-2,4-diones as Efficacious Pan-Inhibitors of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of Anemia.
A 24-Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients.
A highly sensitive and selective UPLC-MS/MS assay for the determination of enarodustat (JTZ-951) in human plasma.
A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat.
A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study.
A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
A phase 3, open-label, single-arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis-stimulating agents.
A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial.
An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects.
Anemia Management in Peritoneal Dialysis: Perspectives From the Asia Pacific Region.
Antianemia Drug Roxadustat (FG-4592) Protects Against Doxorubicin-Induced Cardiotoxicity by Targeting Antiapoptotic and Antioxidative Pathways.
Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review.
Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis.
Daprodustat: First Approval.
Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia.
Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of Anemia.
Discovery of novel 2-[(4-hydroxy-6-oxo-2,3-dihydro-1H-pyridine-5-carbonyl)amino]acetic acid derivatives as HIF prolyl hydroxylase inhibitors for treatment of renal anemia.
Discovery of Orally Bioavailable and Liver-Targeted Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PHD) Inhibitors for the Treatment of Anemia.
Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects.
Effect of the Phosphate Binders Sevelamer Carbonate and Calcium Acetate on the Pharmacokinetics of Roxadustat After Concomitant or Time-separated Administration in Healthy Individuals.
Effectiveness of hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat on renal anemia in non-dialysis-dependent chronic kidney disease: a systematic review and meta-analysis.
Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.
Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis.
Effects of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, on sodium dynamics in hypertensive subtotally nephrectomized rats.
Effects of oral iron and calcium supplement on the pharmacokinetics and pharmacodynamics of molidustat: an oral HIF-PH inhibitor for the treatment of renal anaemia.
Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents.
Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.
Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a systematic review and meta-analysis.
Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: a systematic review and meta-analysis.
Enarodustat to treat anemia in chronic kidney disease.
Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial.
Erythropoietin regulates metabolic response in mice via receptor expression in adipose tissue, brain and bone.
Evaluation of Food and Spherical Carbon Adsorbent Effects on the Pharmacokinetics of Roxadustat in Healthy Nonelderly Adult Male Japanese Subjects.
Evaluation of the Carcinogenic Potential of Roxadustat (FG-4592), a Small Molecule Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase in CD-1 Mice and Sprague Dawley Rats.
Evaluation of the effect of lanthanum carbonate hydrate on the pharmacokinetics of roxadustat in non-elderly healthy adult male subjects.
Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.
HIF prolyl hydroxylase inhibitors for anemia.
HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond.
Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis.
Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation.
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Patients with Renal Anemia: A Meta-Analysis of Randomized Trials.
Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation.
Hypoxia-Inducible Factor Stabilizers: a New Avenue for Reducing BP While Helping Hemoglobin?
Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease.
In response to "Title: Letter to the Editor in response to the article 'Efficacy and safety of HIF prolyl hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis'".
In vivo functions of the prolyl-4-hydroxylase domain oxygen sensors: direct route to the treatment of anaemia and the protection of ischaemic tissues.
Inhibition of firefly luciferase activity by a HIF prolyl hydroxylase inhibitor.
Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study.
Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
Iron metabolism and management: focus on chronic kidney disease.
Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
Iron Therapy in Chronic Kidney Disease: Days of Future Past.
JTZ-951 (enarodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, improves iron utilization and anemia of inflammation: Comparative study against recombinant erythropoietin in rat.
Kidney pericyte hypoxia-inducible factor regulates erythropoiesis but not kidney fibrosis.
Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Novel Compound Induces Erythropoietin Secretion through Liver Effects in Chronic Kidney Disease Patients and Healthy Volunteers.
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective HIF prolyl hydroxylase (PHD) inhibitor.
Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.
Phase 3 Randomized Study Comparing Vadadustat with Darbepoetin Alfa for Anemia in Japanese Patients with Nondialysis-Dependent CKD.
Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD.
Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
Pyrazolo[4,3-d]pyrimidine Derivatives as a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Inhibitor for the Treatment of Anemia.
Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).
Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES).
Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS).
Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis.
Systemic inactivation of hypoxia-inducible factor prolyl 4-hydroxylase 2 in mice protects from alcohol-induced fatty liver disease.
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients.
The PMDA Perspectives on New Oral Prolyl Hydroxylase Domain Enzyme Inhibitors for Renal Anemia.
The problem with transferrin saturation as an indicator of iron 'sufficiency' in chronic kidney disease.
The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.
Treatment of Diabetic Kidney Disease: Current and Future.
Two long-term phase 3 studies of enarodustat (JTZ-951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND-Long and HD-Long studies.
Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open-label study in Japan.
Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients.
Zinc Inhibits HIF-Prolyl Hydroxylase Inhibitor-Aggravated VSMC Calcification Induced by High Phosphate.
[Future perspectives of treatment for anemia in chronic kidney disease (CKD) using hypoxia-inducible factor prolyl hydroxylase inhibitors].
[Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
Anemia, Refractory
Successful treatment of anti-EPO antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor.
Anthrax
Crystal structure of prolyl 4-hydroxylase from Bacillus anthracis.
Arteriosclerosis
Aortic proline hydroxylase in hypoxia induced arteriosclerosis in rabbits.
Elevation of aortic proline hydroxylase: a biochemical defect in experimental arteriosclerosis.
Proline hydroxylase in injury-induced arteriosclerosis.
Arteritis
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.
Arthritis, Rheumatoid
Connective tissue metabolites in serum as markers of disease activity in patients with rheumatoid arthritis.
Increased protocollagen proline hydroxylase activity in synovial tissue in rheumatoid arthritis.
Macrophage specificity of three anti-CD68 monoclonal antibodies (KP1, EBM11, and PGM1) widely used for immunohistochemistry and flow cytometry.
Prolyl hydroxylase domain enzyme 2 is the major player in regulating hypoxic responses in rheumatoid arthritis.
Ascorbic Acid Deficiency
Intracellular retention of procollagen within the endoplasmic reticulum is mediated by prolyl 4-hydroxylase.
Atherosclerosis
Adipocyte Hypoxia-Inducible Factor 2? Suppresses Atherosclerosis by Promoting Adipose Ceramide Catabolism.
Cloning of a novel prolyl 4-hydroxylase subunit expressed in the fibrous cap of human atherosclerotic plaque.
Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis.
Proline hydroxylase activity and collagen content of pigeon aortas with naturally-occurring and cholesterol-aggravated atherosclerosis.
beta-Thalassemia
[Proline hydroxylase (hPH) as marker of hepatic fibrosis in beta thalassemia]
Bone Diseases, Developmental
P4HA1 mutations cause a unique congenital disorder of connective tissue involving tendon, bone, muscle and the eye.
Bone Resorption
'Hypoxia-inducible factor 1-alpha does not regulate osteoclastogenesis but enhances bone resorption activity via prolyl-4-hydroxylase 2'.
Hypoxia-inducible factor 1-alpha does not regulate osteoclastogenesis but enhances bone resorption activity via prolyl-4-hydroxylase 2.
Bowen's Disease
Expression of hypoxia-inducible factor-1?, vascular endothelial growth factor and prolyl hydroxylase domain protein 2 in cutaneous squamous cell carcinoma and precursor lesions and their relationship with histological stages and clinical features.
Brain Injuries
The prolyl 4-hydroxylase inhibitor GSK360A decreases post-stroke brain injury and sensory, motor, and cognitive behavioral deficits.
Brain Ischemia
Hydroxylase inhibition reduces synaptic transmission and protects against a glutamate-induced ischemia in the CA1 region of the rat hippocampus.
Brain Neoplasms
Knockdown of P4HA1 inhibits neovascularization via targeting glioma stem cell-endothelial cell transdifferentiation and disrupting vascular basement membrane.
Breast Neoplasms
Chemical synthesis and biochemical characterization of a biotinylated derivative of 17beta-estradiol with a long side chain covalently attached to its C-7alpha position.
Collagen prolyl 4-hydroxylase 1 is essential for HIF-1? stabilization and TNBC chemoresistance.
Collagen Type X Alpha 1 (COL10A1) Contributes to Cell Proliferation, Migration, and Invasion by Targeting Prolyl 4-Hydroxylase Beta Polypeptide (P4HB) in Breast Cancer.
Deficiency of Follistatin-Like Protein 1 Accelerates the Growth of Breast Cancer Cells at Lung Metastatic Sites.
Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer.
Expression of cancer-associated fibroblast related proteins in metastatic breast cancer: an immunohistochemical analysis.
Identification of Potential Diagnostic and Prognostic Values of P4HA1 Expression in Lung Cancer, Breast Cancer, and Head and Neck Cancer.
IL-4-induced Stat6 activities affect apoptosis and gene expression in breast cancer cells.
Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer.
Mitochondrial malic enzyme 2 promotes breast cancer metastasis via stabilizing HIF-1? under hypoxia.
P4HA1 is a new regulator of the HIF-1 pathway in breast cancer.
Profiling and comparative analysis of glycoproteins in Hs578BST and Hs578T and investigation of prolyl 4-hydroxylase alpha polypeptide II expression and influence in breast cancer cells.
Prognostic and diagnostic roles of prolyl 4-hydroxylase subunit ? members in breast cancer.
Prolyl-4-hydroxylase ? subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition.
Systemic Multi-Omics Analysis Reveals Amplified P4HA1 Gene Associated With Prognostic and Hypoxic Regulation in Breast Cancer.
Transketolase regulates the metabolic switch to control breast cancer cell metastasis via the alpha-ketoglutarate signaling pathway.
[Correlation of the methylation status of CpG islands in the promoter region of 10 genes with the 5-Fu chemosensitivity in 3 breast cancer cell lines]
[Different expression of liver-specific insulin-like growth factor I gene in breast cancer; expression with mice]
Capsule Opacification
Immunolocalization of prolyl 4-hydroxylase in rabbit lens epithelial cells.
Carcinogenesis
Circular RNA EGLN3 silencing represses renal cell carcinoma progression through the miR-1224-3p/HMGXB3 axis.
Collagen prolyl 4-hydroxylase 2 predicts worse prognosis and promotes glycolysis in cervical cancer.
Downregulation of Proline Hydroxylase 2 and Upregulation of Hypoxia-Inducible Factor 1? are Associated with Endometrial Cancer Aggressiveness.
High P4HA1 expression is an independent prognostic factor for poor overall survival and recurrent-free survival in head and neck squamous cell carcinoma.
Overexpression of P4HB is correlated with poor prognosis in human clear cell renal cell carcinoma.
Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to breast tumorigenesis.
Suppression of glioma progression by egln3.
Systemic Multi-Omics Analysis Reveals Amplified P4HA1 Gene Associated With Prognostic and Hypoxic Regulation in Breast Cancer.
Tumor PHD2 expression is correlated with clinical features and prognosis of patients with HCC receiving liver resection.
Carcinoma
Autoantibody against hypoxia-inducible factor prolyl hydroxylase-3 is a potential serological marker for renal cell carcinoma.
Circular RNA EGLN3 silencing represses renal cell carcinoma progression through the miR-1224-3p/HMGXB3 axis.
Curcumin provides potential protection against the activation of hypoxia and prolyl 4-hydroxylase inhibitors on prostate-specific antigen expression in human prostate carcinoma cells.
Desmoplastic response in scirrhous gastric carcinoma: imbalance between collagen synthesis and degradation.
Expression of cancer-associated fibroblast-related proteins differs between invasive lobular carcinoma and invasive ductal carcinoma.
Expression of hypoxia-inducible factor-1?, vascular endothelial growth factor and prolyl hydroxylase domain protein 2 in cutaneous squamous cell carcinoma and precursor lesions and their relationship with histological stages and clinical features.
Expression of prolyl 4-hydroxylase beta-polypeptide in non-small cell lung cancer treated with Chinese medicines.
HIF prolyl hydroxylase PHD3 regulates translational machinery and glucose metabolism in clear cell renal cell carcinoma.
High P4HA1 expression is an independent prognostic factor for poor overall survival and recurrent-free survival in head and neck squamous cell carcinoma.
Hypoxia-inducible factor (HIF)-independent expression mechanism and novel function of HIF prolyl hydroxylase-3 in renal cell carcinoma.
Identification of PRDX4 and P4HA2 as Metastasis-Associated Proteins in Oral Cavity Squamous Cell Carcinoma by Comparative Tissue Proteomics of Microdissected Specimens Using iTRAQ Technology.
Onconeuronal antigen Cdr2 correlates with HIF prolyl-4-hydroxylase PHD1 and worse prognosis in renal cell carcinoma.
Over-expression of prolyl hydroxylase-1 blocks NF-?B-mediated cyclin D1 expression and proliferation in lung carcinoma cells.
Overexpression and Nuclear Translocation of Hypoxia-Inducible Factor Prolyl Hydroxylase PHD2 in Head and Neck Squamous Cell Carcinoma Is Associated with Tumor Aggressiveness.
Overexpression of P4HB is correlated with poor prognosis in human clear cell renal cell carcinoma.
P4HA1: A single-gene surrogate of hypoxia signatures in oral squamous cell carcinoma patients.
Prolyl 4-hydroxylase subunit alpha 3 presents a cancer promotive function in head and neck squamous cell carcinoma via regulating epithelial-mesenchymal transition.
Prolyl hydroxylase-3 is a novel renal cell carcinoma biomarker.
Prolyl-4-hydroxylase ? subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).
Prolyl-4-Hydroxylase ? Subunit 2 as a Novel Potential Biomarker for Predicting the Prognosis of Epithelial Ovarian Carcinoma.
Carcinoma, Ductal
Prolyl-4-hydroxylase ? subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).
Carcinoma, Hepatocellular
Aspirin targets P4HA2 through inhibiting NF-?B and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma.
Hepatitis B virus X protein promotes the development of liver fibrosis and hepatoma through downregulation of miR-30e targeting P4HA2 mRNA.
MiR-30e suppresses proliferation of hepatoma cells via targeting prolyl 4-hydroxylase subunit alpha-1 (P4HA1) mRNA.
Molecular cloning of cDNA encoding a 55-kDa multifunctional thyroid hormone binding protein of skeletal muscle sarcoplasmic reticulum.
Molecular cloning of the beta-subunit of human prolyl 4-hydroxylase. This subunit and protein disulphide isomerase are products of the same gene.
Protocollagen proline hydroxylase in sera of Ugandans with hepatocellular carcinoma.
Carcinoma, Intraductal, Noninfiltrating
Differential Expression of Cancer-Associated Fibroblast-Related Proteins in Ductal Carcinoma in situ According to Molecular Subtype and Stromal Histology.
Prolyl-4-hydroxylase ? subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).
Carcinoma, Non-Small-Cell Lung
Expression of hypoxia-inducible factor prolyl hydroxylase 3 HIFPH3 in human non-small cell lung cancer (NSCLC) and its correlation with prognosis.
Expression of prolyl 4-hydroxylase beta-polypeptide in non-small cell lung cancer treated with Chinese medicines.
Expression of prolyl-hydroxylases PHD-1, 2 and 3 and of the asparagine hydroxylase FIH in non-small cell lung cancer relates to an activated HIF pathway.
Carcinoma, Ovarian Epithelial
Prolyl-4-Hydroxylase ? Subunit 2 as a Novel Potential Biomarker for Predicting the Prognosis of Epithelial Ovarian Carcinoma.
Carcinoma, Renal Cell
Autoantibody against hypoxia-inducible factor prolyl hydroxylase-3 is a potential serological marker for renal cell carcinoma.
Circular RNA EGLN3 silencing represses renal cell carcinoma progression through the miR-1224-3p/HMGXB3 axis.
HIF prolyl hydroxylase PHD3 regulates translational machinery and glucose metabolism in clear cell renal cell carcinoma.
Hypoxia-inducible factor (HIF)-independent expression mechanism and novel function of HIF prolyl hydroxylase-3 in renal cell carcinoma.
Onconeuronal antigen Cdr2 correlates with HIF prolyl-4-hydroxylase PHD1 and worse prognosis in renal cell carcinoma.
Overexpression of P4HB is correlated with poor prognosis in human clear cell renal cell carcinoma.
Prolyl hydroxylase-3 is a novel renal cell carcinoma biomarker.
Carcinoma, Squamous Cell
Expression of hypoxia-inducible factor-1?, vascular endothelial growth factor and prolyl hydroxylase domain protein 2 in cutaneous squamous cell carcinoma and precursor lesions and their relationship with histological stages and clinical features.
High P4HA1 expression is an independent prognostic factor for poor overall survival and recurrent-free survival in head and neck squamous cell carcinoma.
Identification of PRDX4 and P4HA2 as Metastasis-Associated Proteins in Oral Cavity Squamous Cell Carcinoma by Comparative Tissue Proteomics of Microdissected Specimens Using iTRAQ Technology.
Overexpression and Nuclear Translocation of Hypoxia-Inducible Factor Prolyl Hydroxylase PHD2 in Head and Neck Squamous Cell Carcinoma Is Associated with Tumor Aggressiveness.
Prolyl 4-hydroxylase subunit alpha 3 presents a cancer promotive function in head and neck squamous cell carcinoma via regulating epithelial-mesenchymal transition.
Cardiomegaly
Early intervention with a potent endothelin-A/endothelin-B receptor antagonist aggravates left ventricular remodeling after myocardial infarction in rats.
Protocollagen proline hydroxylase activity in rat heart during experimental cardiac hypertrophy.
Cardiomyopathies
A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats.
Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy.
Cardiomyopathy, Dilated
Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury.
Cataract
Genome-wide analysis of methylation in giant pandas with cataract by methylation-dependent restriction-site associated DNA sequencing (MethylRAD).
Immunolocalization of prolyl 4-hydroxylase in rabbit lens epithelial cells.
Immunolocalization of prolyl 4-hydroxylase subunits, alpha-smooth muscle actin, and extracellular matrix components in human lens capsules with lens implants.
Cholangiocarcinoma
USP9X promotes apoptosis in cholangiocarcinoma by modulation expression of KIF1B? via deubiquitinating EGLN3.
Chondrosarcoma
Immunofluorescence localization of prolyl 4-hydroxylase isoenzymes and type I and II collagens in bone tumours: type I enzyme predominates in osteosarcomas and chondrosarcomas, whereas type II enzyme predominates in their benign counterparts.
Colitis
Dynamics of Prolyl Hydroxylases Levels During Disease Progression in Experimental Colitis.
Haematopoietic prolyl hydroxylase-1 deficiency promotes M2 macrophage polarization and is both necessary and sufficient to protect against experimental colitis.
Loss of Prolyl Hydroxylase-1 Protects Against Colitis Through Reduced Epithelial Cell Apoptosis and Increased Barrier Function.
Colitis, Ulcerative
Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective HIF prolyl hydroxylase (PHD) inhibitor.
Colonic Neoplasms
Comprehensive Analysis of Gene Expression Profiles Identifies a P4HA1-Related Gene Panel as a Prognostic Model in Colorectal Cancer Patients.
Colorectal Neoplasms
Corrigendum to 'Targeting P4HA1 with a Small Molecule Inhibitor in a Colorectal Cancer PDX Model' [Translational Oncology 13 (2020) 100754].
P4HA1 regulates human colorectal cancer cells through HIF1?-mediated Wnt signaling.
Prolyl 4-hydroxylase alpha 1 protein expression risk-stratifies early stage colorectal cancer.
Prolyl Hydroxylase-3 Is Downregulated in Colorectal Cancer Cells and Inhibits IKKbeta, Independent of Hydroxylase Activity.
Targeting P4HA1 with a Small Molecule Inhibitor in a Colorectal Cancer PDX Model.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
P4HA1 mutations cause a unique congenital disorder of connective tissue involving tendon, bone, muscle and the eye.
Contracture
Auxiliary proteins that facilitate formation of collagen-rich deposits in the posterior knee capsule in a rabbit-based joint contracture model.
P4HA1 mutations cause a unique congenital disorder of connective tissue involving tendon, bone, muscle and the eye.
COVID-19
HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons.
Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells.
Diabetic Nephropathies
The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease.
Endometrial Neoplasms
Downregulation of Proline Hydroxylase 2 and Upregulation of Hypoxia-Inducible Factor 1? are Associated with Endometrial Cancer Aggressiveness.
Endometriosis
An investigation of the effects of endometriosis on the proteome of human eutopic endometrium: a heterogeneous tissue with a complex disease.
Fatty Liver
Liver protocollagen proline hydroxylase in human liver diseases and experimental liver fibrosis.
Systemic inactivation of hypoxia-inducible factor prolyl 4-hydroxylase 2 in mice protects from alcohol-induced fatty liver disease.
Fibroma
Phenotypic characterisation of stellate and giant cells in giant cell fibroma by immunocytochemistry.
Fibrosarcoma
Regulation of collagen prolyl 4-hydroxylase and matrix metalloproteinases in fibrosarcoma cells by hypoxia.
Giant Cell Arteritis
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.
Glaucoma
Effect of fibrostatin C, an inhibitor of prolyl 4-hydroxylase, on collagen secretion by human Tenon's capsule fibroblasts in vitro.
Glioblastoma
Defective p53 antiangiogenic signaling in glioblastoma.
Endoplasmic reticulum chaperone prolyl 4-hydroxylase, beta polypeptide (P4HB) promotes malignant phenotypes in glioma via MAPK signaling.
P4HA1 as an unfavorable prognostic marker promotes cell migration and invasion of glioblastoma via inducing EMT process under hypoxia microenvironment.
P4HA2 promotes cell proliferation and migration in glioblastoma.
P4HA2 Promotes Epithelial-to-Mesenchymal Transition and Glioma Malignancy through the Collagen-Dependent PI3K/AKT Pathway.
Glioma
Endoplasmic reticulum chaperone prolyl 4-hydroxylase, beta polypeptide (P4HB) promotes malignant phenotypes in glioma via MAPK signaling.
Identification of P4HA1 as a prognostic biomarker for high-grade gliomas.
Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways.
Knockdown of P4HA1 inhibits neovascularization via targeting glioma stem cell-endothelial cell transdifferentiation and disrupting vascular basement membrane.
P4HA1 Down-Regulation Inhibits Glioma Invasiveness by Promoting M1 Microglia Polarization.
P4HA2 Promotes Epithelial-to-Mesenchymal Transition and Glioma Malignancy through the Collagen-Dependent PI3K/AKT Pathway.
Potential regulation of glioma through the induction of apoptosis signaling via Egl-9 family hypoxia-inducible factor 3.
Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines.
Suppression of glioma progression by egln3.
Glucose Intolerance
Prolyl hydroxylase domain protein 2 plays a critical role in diet-induced obesity and glucose intolerance.
Granuloma
Collagen proline hydroxylase in wound healing, granuloma formation, scurvy, and growth.
Head and Neck Neoplasms
Identification of Potential Diagnostic and Prognostic Values of P4HA1 Expression in Lung Cancer, Breast Cancer, and Head and Neck Cancer.
Hemochromatosis
Familial hemochromatosis. Physiologic studies in the precirrhotic stage of the disease.
Hemorrhagic Stroke
"Branched tail" oxyquinoline inhibitors of HIF prolyl hydroxylase: Early Evaluation of Toxicity and Metabolism Using Liver-on-a-chip.
Hepatitis B
Hepatitis B virus X protein promotes the development of liver fibrosis and hepatoma through downregulation of miR-30e targeting P4HA2 mRNA.
Hepatitis B, Chronic
Serum markers for connective tissue turnover in patients with chronic hepatitis B and chronic hepatitis C: a comparative analysis.
Hepatitis C, Chronic
Serum markers for connective tissue turnover in patients with chronic hepatitis B and chronic hepatitis C: a comparative analysis.
Hepatitis, Alcoholic
Hepatic collagen proline hydroxylase activity in alcoholic hepatitis: effect of d-penicillamine.
Hepatic collagen proline hydroxylase activity in alcoholic liver disease.
Hodgkin Disease
Strong Prolyl Hydroxylase Domain 1 Expression Predicts Poor Outcome in Radiotherapy-treated Patients with Classical Hodgkin's Lymphoma.
Huntington Disease
HIF prolyl hydroxylase inhibitors prevent neuronal death induced by mitochondrial toxins: therapeutic implications for Huntington's disease and Alzheimer's disease.
Infections
HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons.
Hypoxia Induces Permeability and Giant Cell Responses of ANDV Infected Pulmonary Endothelial Cells by Activating the mTOR-S6K Signaling Pathway.
Insulin Resistance
Cross-talk between hypoxia and insulin signaling through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetes.
Hypoxia-inducible factor prolyl hydroxylase 1 (PHD1) deficiency promotes hepatic steatosis and liver-specific insulin resistance in mice.
Intestinal Volvulus
Characterization and expression of enzymatically active recombinant filarial prolyl 4-hydroxylase.
Iron Deficiencies
The problem with transferrin saturation as an indicator of iron 'sufficiency' in chronic kidney disease.
The prolyl 4-hydroxylase inhibitor ethyl-3,4-dihydroxybenzoate generates effective iron deficiency in cultured cells.
Iron Overload
Familial hemochromatosis: characteristics of the precirrhotic stage in a large kindred.
Ischemic Stroke
Inhibition of HIF prolyl-4-hydroxylases by FG-4497 reduces brain tissue injury and edema formation during ischemic stroke.
Joint Instability
P4HA1 mutations cause a unique congenital disorder of connective tissue involving tendon, bone, muscle and the eye.
Keloid
Collagen biosynthesis in normal human skin, normal and hypertrophic scar and keloid.
Collagen gene expression in keloids: analysis of collagen metabolism and type I, III, IV, and V procollagen mRNAs in keloid tissue and keloid fibroblast cultures.
Keratoconus
Increase in type I and type IV collagenolytic activity in primary cultures of keratoconus cornea.
Protein-related abnormalities in keratoconus.
Keratosis, Seborrheic
Expression of hypoxia-inducible factor-1?, vascular endothelial growth factor and prolyl hydroxylase domain protein 2 in cutaneous squamous cell carcinoma and precursor lesions and their relationship with histological stages and clinical features.
Kidney Diseases
Laser capture microdissection and multiplex-tandem PCR analysis of proximal tubular epithelial cell signaling in human kidney disease.
Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis.
Kidney Failure, Chronic
A Mass Balance Study of 14 C-Labeled JTZ-951 (Enarodustat), a Novel Orally Available Erythropoiesis-Stimulating Agent, in Patients With End-Stage Renal Disease on Hemodialysis.
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
Kidney Neoplasms
Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response.
Liposarcoma
Characterization of a human cell line derived from liposarcoma tissue: is the beta subunit of prolyl 4-hydroxylase specific for a fibroblastic phenotype in culture cells?
Liver Cirrhosis
Hepatitis B virus X protein promotes the development of liver fibrosis and hepatoma through downregulation of miR-30e targeting P4HA2 mRNA.
Is serum prolyl 4-hydroxylase useful as noninvasive marker of liver fibrosis in patients with biliary atresia?
Liver protocollagen proline hydroxylase in human liver diseases and experimental liver fibrosis.
Mechanisms by which acute phase proteins enhance development of liver fibrosis: effects on collagenase and prolyl-4-hydroxylase activity in the rat liver.
New prolyl 4-hydroxylase inhibitor reduces procollagen gene expression and enzyme-altered lesions in rat liver cirrhosis.
Preventive effect of malotilate on dimethylnitrosamine-induced liver fibrosis in the rat.
Prolyl 4-hydroxylase inhibitor (HOE 077) inhibits pig serum-induced rat liver fibrosis by preventing stellate cell activation.
Prolyl 4-hydroxylase inhibitor (HOE 077) prevents TIMP-1 gene expression in rat liver fibrosis.
Selective inhibition of hepatic collagen accumulation in experimental liver fibrosis in rats by a new prolyl 4-hydroxylase inhibitor.
The prolyl 4-hydroxylase inhibitor HOE 077 prevents activation of Ito cells, reducing procollagen gene expression in rat liver fibrosis induced by choline-deficient L-amino acid-defined diet.
Liver Cirrhosis, Biliary
Fibrosis of the liver in rats induced by bile duct ligation. Effects of inhibition by prolyl 4-hydroxylase.
Hepatic collagen proline hydroxylase activity in primary biliary cirrhosis.
Liver Diseases
Liver protocollagen proline hydroxylase in human liver diseases and experimental liver fibrosis.
Studies on serum immunoreactive prolyl 4-hydroxylase in liver diseases--its elevation both in hepatocellular damage and cholestatic diseases.
Systemic inactivation of hypoxia-inducible factor prolyl 4-hydroxylase 2 in mice protects from alcohol-induced fatty liver disease.
Liver Diseases, Alcoholic
Hepatic collagen proline hydroxylase activity in alcoholic liver disease.
Liver Failure
Hepatic retinopathy: morphological features of retinal glial (Müller) cells accompanying hepatic failure.
Liver Neoplasms
Hepatitis B virus X protein promotes the development of liver fibrosis and hepatoma through downregulation of miR-30e targeting P4HA2 mRNA.
P4HB modulates epithelial-mesenchymal transition and the ?-catenin/Snail pathway influencing chemoresistance in liver cancer cells.
Lung Neoplasms
Collagen modifying enzyme P4HA1 is overexpressed and plays a role in lung adenocarcinoma.
Effects of Yiqi Chutan Tang on the Proteome in LEWIS Lung Cancer in Mice.
Expression of hypoxia-inducible factor prolyl hydroxylase 3 HIFPH3 in human non-small cell lung cancer (NSCLC) and its correlation with prognosis.
Expression of prolyl 4-hydroxylase beta-polypeptide in non-small cell lung cancer treated with Chinese medicines.
Expression of prolyl-hydroxylases PHD-1, 2 and 3 and of the asparagine hydroxylase FIH in non-small cell lung cancer relates to an activated HIF pathway.
Identification of Potential Diagnostic and Prognostic Values of P4HA1 Expression in Lung Cancer, Breast Cancer, and Head and Neck Cancer.
RASSF1A controls tissue stiffness and cancer stem-like cells in lung adenocarcinoma.
Lymphatic Metastasis
Expression of hypoxia-inducible factor prolyl hydroxylase 3 HIFPH3 in human non-small cell lung cancer (NSCLC) and its correlation with prognosis.
High P4HA1 expression is an independent prognostic factor for poor overall survival and recurrent-free survival in head and neck squamous cell carcinoma.
Lymphoma
Localization of collagen modifying enzymes on fibroblastic reticular cells and follicular dendritic cells in non-neoplastic and neoplastic lymphoid tissues.
Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin.
The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma.
Lymphoma, B-Cell
Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin.
The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.
Lymphoma, Large B-Cell, Diffuse
Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin.
Melanoma
A reliable set of reference genes to normalize oxygen-dependent cytoglobin gene expression levels in melanoma.
Collagen Prolyl Hydroxylases Are Bifunctional Growth Regulators in Melanoma.
New phenotypical and ultrastructural findings in spindle cell (desmoplastic/neurotropic) melanoma.
Prolyl 4-hydroxylase subunit alpha 1 (P4HA1) is a biomarker of poor prognosis in primary melanomas, and its depletion inhibits melanoma cell invasion and disrupts tumor blood vessel walls.
Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth.
Metabolic Diseases
Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective HIF prolyl hydroxylase (PHD) inhibitor.
Mitochondrial Diseases
Multi-OMICS study of a CHCHD10 variant causing ALS demonstrates metabolic rewiring and activation of endoplasmic reticulum and mitochondrial unfolded protein responses.
Monoclonal Gammopathy of Undetermined Significance
The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.
Multiple Myeloma
The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.
Muscle Weakness
P4HA1 mutations cause a unique congenital disorder of connective tissue involving tendon, bone, muscle and the eye.
Muscular Atrophy
Global alternative splicing landscape of skeletal muscle atrophy induced by hindlimb unloading.
Myocardial Infarction
Activation of hypoxia-inducible factor-1 via prolyl-4 hydoxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium.
Chronic Inhibition of Hypoxia-Inducible Factor (HIF) Prolyl 4-Hydroxylase Improves Ventricular Performance, Remodeling and Vascularity Following Myocardial Infarction in the Rat.
Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat.
Depletion of Endothelial Prolyl Hydroxylase Domain Protein 2 and 3 Promotes Cardiomyocyte Proliferation and Prevents Ventricular Failure Induced by Myocardial Infarction.
Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction.
Myocardium-targeted transplantation of PHD2 shRNA-modified bone mesenchymal stem cells through ultrasound-targeted microbubble destruction protects the heart from acute myocardial infarction.
Pre- and post-conditional inhibition of prolyl-4-hydroxylase domain enzymes protects the heart from an ischemic insult.
Myocardial Ischemia
Activation of hypoxia response in endothelial cells contributes to ischemic cardioprotection.
Myopia
Autosomal-dominant myopia associated to a novel P4HA2 missense variant and defective collagen hydroxylation.
Mutations of P4HA2 encoding prolyl 4-hydroxylase 2 are associated with nonsyndromic high myopia.
P4HA1 mutations cause a unique congenital disorder of connective tissue involving tendon, bone, muscle and the eye.
Neoplasm Metastasis
Blocking drug-induced autophagy with chloroquine in HCT-116 colon cancer cells enhances DC maturation and T cell responses induced by tumor cell lysate.
Expression of cancer-associated fibroblast related proteins in metastatic breast cancer: an immunohistochemical analysis.
Expression of hypoxia-inducible factor prolyl hydroxylase 3 HIFPH3 in human non-small cell lung cancer (NSCLC) and its correlation with prognosis.
Identification of a novel glycolysis-related gene signature for predicting the prognosis of osteosarcoma patients.
Identification of PRDX4 and P4HA2 as Metastasis-Associated Proteins in Oral Cavity Squamous Cell Carcinoma by Comparative Tissue Proteomics of Microdissected Specimens Using iTRAQ Technology.
Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer.
LncRNA PCGEM1 enhances metastasis and gastric cancer invasion through targeting of miR-129-5p to regulate P4HA2 expression.
Metabolic Rewiring and the Characterization of Oncometabolites.
MiR-122 inhibits epithelial mesenchymal transition by regulating P4HA1 in ovarian cancer cells.
Overexpression of hydroxyproline via EGLN/HIF1A is associated with distant metastasis in pancreatic cancer.
Prolyl-4-hydroxylase ? subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition.
Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to breast tumorigenesis.
Targeting P4HA1 with a Small Molecule Inhibitor in a Colorectal Cancer PDX Model.
The E2F transcription factors regulate tumor development and metastasis in a mouse model of metastatic breast cancer.
The Genes-Candidates for Prognostic Markers of Metastasis by Expression Level in Clear Cell Renal Cell Cancer.
The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression.
Transketolase regulates the metabolic switch to control breast cancer cell metastasis via the alpha-ketoglutarate signaling pathway.
Neoplasms
A screen for inducers of p21(waf1/cip1) identifies HIF prolyl hydroxylase inhibitors as neuroprotective agents with antitumor properties.
A staging system for hepatocellular carcinoma: prognostic factors in Ugandan patients.
Abrogation of esophageal carcinoma development in miR-31 knockout rats.
Activation of the Unfolded Protein Response via Inhibition of Protein Disulfide Isomerase Decreases the Capacity for DNA Repair to Sensitize Glioblastoma to Radiotherapy.
Apicidin upregulates PHD2 prolyl hydroxylase gene expression in cervical cancer cells.
Aspirin targets P4HA2 through inhibiting NF-?B and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma.
Blocking drug-induced autophagy with chloroquine in HCT-116 colon cancer cells enhances DC maturation and T cell responses induced by tumor cell lysate.
Characterization of Glycolysis-Associated Molecules in the Tumor Microenvironment Revealed by Pan-Cancer Tissues and Lung Cancer Single Cell Data.
Circ_101341 Deteriorates the Progression of Clear Cell Renal Cell Carcinoma Through the miR- 411/EGLN3 Axis.
Collagen prolyl 4-hydroxylase 1 is essential for HIF-1? stabilization and TNBC chemoresistance.
Collagen prolyl 4-hydroxylase 2 predicts worse prognosis and promotes glycolysis in cervical cancer.
Collagen prolyl 4-hydroxylases modify tumor progression.
Collagen Prolyl Hydroxylases Are Bifunctional Growth Regulators in Melanoma.
Collagen Type X Alpha 1 (COL10A1) Contributes to Cell Proliferation, Migration, and Invasion by Targeting Prolyl 4-Hydroxylase Beta Polypeptide (P4HB) in Breast Cancer.
Defective p53 antiangiogenic signaling in glioblastoma.
Differential protein expression in primary breast cancer and matched axillary node metastasis.
EGLN3 prolyl hydroxylase regulates skeletal muscle differentiation and myogenin protein stability.
Enzyme pathology of the liver in patients with and without nonhepatic cancer.
Expression of cancer-associated fibroblast-related proteins differs between invasive lobular carcinoma and invasive ductal carcinoma.
Expression of cancer-associated fibroblast-related proteins in adipose stroma of breast cancer.
Expression of cancer-associated fibroblast-related proteins in thyroid papillary carcinoma.
Fibrosis in undifferentiated (anaplastic) thyroid carcinomas: evidence for a dual action of tumour cells in collagen type I synthesis.
HIF prolyl hydroxylase-3 mediates alpha-ketoglutarate-induced apoptosis and tumor suppression.
High P4HA1 expression is an independent prognostic factor for poor overall survival and recurrent-free survival in head and neck squamous cell carcinoma.
Homology modeling and molecular dynamics simulation of the HIF2? degradation-related HIF2?-VHL complex.
Hypoxia-inducible factor prolyl-4-hydroxylase-1 is a convergent point in the reciprocal negative regulation of NF-?B and p53 signaling pathways.
Identification of an Metabolic Related Risk Signature Predicts Prognosis in Cervical Cancer and Correlates With Immune Infiltration.
Identification of P4HA1 as a prognostic biomarker for high-grade gliomas.
Identification of Potential Diagnostic and Prognostic Values of P4HA1 Expression in Lung Cancer, Breast Cancer, and Head and Neck Cancer.
Identification of PRDX4 and P4HA2 as Metastasis-Associated Proteins in Oral Cavity Squamous Cell Carcinoma by Comparative Tissue Proteomics of Microdissected Specimens Using iTRAQ Technology.
Immunofluorescence localization of prolyl 4-hydroxylase isoenzymes and type I and II collagens in bone tumours: type I enzyme predominates in osteosarcomas and chondrosarcomas, whereas type II enzyme predominates in their benign counterparts.
Inactivation of HIF-prolyl 4-hydroxylases 1, 2 and 3 in NG2-expressing cells induces HIF2-mediated neurovascular expansion independent of erythropoietin.
Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer.
Induction of fibroblast-like cells from CD34(+) progenitor cells of the bone marrow in rheumatoid arthritis.
Inhibition of Pancreatic Stellate Cell Activation by Halofuginone Prevents Pancreatic Xenograft Tumor Development.
Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways.
Knockdown of P4HA1 inhibits neovascularization via targeting glioma stem cell-endothelial cell transdifferentiation and disrupting vascular basement membrane.
L-Mimosine blocks cell proliferation via upregulation of B-cell translocation gene 2 and N-myc downstream regulated gene 1 in prostate carcinoma cells.
Low P4HA2 and high PRTN3 expression predicts poor survival in patients with pancreatic cancer.
LOXL4 knockdown enhances tumor growth and lung metastasis through collagen-dependent extracellular matrix changes in triple-negative breast cancer.
MiR-30e suppresses proliferation of hepatoma cells via targeting prolyl 4-hydroxylase subunit alpha-1 (P4HA1) mRNA.
Myofibroblasts in pulmonary and brain metastases of alveolar soft-part sarcoma: a novel target for treatment?
Neuronal Apoptosis by Prolyl Hydroxylation: Implication in Nervous System Tumors and the Warburg Conundrum.
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer.
New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein.
Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response.
Overexpression and Nuclear Translocation of Hypoxia-Inducible Factor Prolyl Hydroxylase PHD2 in Head and Neck Squamous Cell Carcinoma Is Associated with Tumor Aggressiveness.
Overexpression of P4HA1 Is Correlated with Poor Survival and Immune Infiltrates in Lung Adenocarcinoma.
Overexpression of P4HB is correlated with poor prognosis in human clear cell renal cell carcinoma.
Overexpression of the Oxygen Sensors PHD-1, PHD-2, PHD-3, and FIH Is Associated with Tumor Aggressiveness in Pancreatic Endocrine Tumors.
P4HA1/HIF1? feedback loop drives the glycolytic and malignant phenotypes of pancreatic cancer.
P4HA2 contributes to cervical cancer progression via inducing epithelial-mesenchymal transition.
P4HA2 Promotes Epithelial-to-Mesenchymal Transition and Glioma Malignancy through the Collagen-Dependent PI3K/AKT Pathway.
P4HB: A novel diagnostic and prognostic biomarker for bladder carcinoma.
Potential regulation of glioma through the induction of apoptosis signaling via Egl-9 family hypoxia-inducible factor 3.
Prolyl 4-hydroxylase subunit alpha 1 (P4HA1) is a biomarker of poor prognosis in primary melanomas, and its depletion inhibits melanoma cell invasion and disrupts tumor blood vessel walls.
Prolyl 4-hydroxylase subunit alpha 3 presents a cancer promotive function in head and neck squamous cell carcinoma via regulating epithelial-mesenchymal transition.
Prolyl-4-hydroxylase ? subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).
Prolyl-4-Hydroxylase ? Subunit 2 as a Novel Potential Biomarker for Predicting the Prognosis of Epithelial Ovarian Carcinoma.
Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to breast tumorigenesis.
RASSF1A controls tissue stiffness and cancer stem-like cells in lung adenocarcinoma.
Research Resource: Transcriptional Profiling Reveals Different Pseudohypoxic Signatures in SDHB and VHL-Related Pheochromocytomas.
Suppression of glioma progression by egln3.
Systematic Analysis of the Expression and Prognostic Significance of P4HA1 in Pancreatic Cancer and Construction of a lncRNA-miRNA-P4HA1 Regulatory Axis.
Targeted Inhibition of P4HB Promotes Cell Sensitivity to Gemcitabine in Urothelial Carcinoma of the Bladder.
Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth.
Targeting P4HA1 with a Small Molecule Inhibitor in a Colorectal Cancer PDX Model.
Targeting the CBP/?-Catenin Interaction to Suppress Activation of Cancer-Promoting Pancreatic Stellate Cells.
TGF-?-dependent reprogramming of amino acid metabolism induces epithelial-mesenchymal transition in non-small cell lung cancers.
The Choice of Candidates in Survival Markers Based on Coordinated Gene Expression in Renal Cancer.
The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma.
The contributions of HIF-target genes to tumor growth in RCC.
The effect of lymphoma and other neoplasms on hepatic and plasma enzymes of the host rat.
The kinesin KIF1B{beta} acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor.
The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression.
The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.
Transketolase regulates the metabolic switch to control breast cancer cell metastasis via the alpha-ketoglutarate signaling pathway.
Tumor PHD2 expression is correlated with clinical features and prognosis of patients with HCC receiving liver resection.
Tumor Suppression by p53 Is Mediated in Part by the Antiangiogenic Activity of Endostatin and Tumstatin.
Tumor-expressed collagens can modulate immune cell function through the inhibitory collagen receptor LAIR-1.
Two new mutations in the HIF2A gene associated with erythrocytosis.
Update on mutations in the HIF: EPO pathway and their role in erythrocytosis.
Use of novel monoclonal antibodies to determine the expression and distribution of the hypoxia regulatory factors PHD-1, PHD-2, PHD-3 and FIH in normal and neoplastic human tissues.
USP9X promotes apoptosis in cholangiocarcinoma by modulation expression of KIF1B? via deubiquitinating EGLN3.
Nervous System Neoplasms
Neuronal Apoptosis by Prolyl Hydroxylation: Implication in Nervous System Tumors and the Warburg Conundrum.
Neurodegenerative Diseases
Proteome response to ochratoxin A-induced apoptotic cell death in mouse hippocampal HT22 cells.
Neurofibroma
Factor-XIIIa-positive cells in normal peripheral nerves and cutaneous neurofibromas of type-1 neurofibromatosis.
Non-alcoholic Fatty Liver Disease
HIF-P4H-2 inhibition enhances intestinal fructose metabolism and induces thermogenesis protecting against NAFLD.
Integrated Analysis of Multiple Microarray Studies to Identify Novel Gene Signatures in Non-alcoholic Fatty Liver Disease.
Obesity
A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats.
HIF Prolyl 4-Hydroxylase-2 Inhibition Improves Glucose and Lipid Metabolism and Protects Against Obesity and Metabolic Dysfunction.
Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis.
Prolyl hydroxylase domain protein 2 plays a critical role in diet-induced obesity and glucose intolerance.
Obesity, Morbid
Hepatic collagen proline hydroxylase activity in hepatic disease following jejunoileal bypass for morbid obesity.
Osteoarthritis
Induction of fibroblast-like cells from CD34(+) progenitor cells of the bone marrow in rheumatoid arthritis.
Macrophage specificity of three anti-CD68 monoclonal antibodies (KP1, EBM11, and PGM1) widely used for immunohistochemistry and flow cytometry.
Regulation of type II collagen synthesis during osteoarthritis by prolyl-4-hydroxylases: possible influence of low oxygen levels.
Osteonecrosis
Hypoxia-inducible factor prolyl hydroxylase inhibitor prevents steroid-associated osteonecrosis of the femoral head in rabbits by promoting angiogenesis and inhibiting apoptosis.
Osteosarcoma
HIF in vascular development and tumour angiogenesis.
Identification of a novel glycolysis-related gene signature for predicting the prognosis of osteosarcoma patients.
Immunofluorescence localization of prolyl 4-hydroxylase isoenzymes and type I and II collagens in bone tumours: type I enzyme predominates in osteosarcomas and chondrosarcomas, whereas type II enzyme predominates in their benign counterparts.
Ovarian Neoplasms
MiR-122 inhibits epithelial mesenchymal transition by regulating P4HA1 in ovarian cancer cells.
The plasma peptides of ovarian cancer.
Pancreatic Neoplasms
Low P4HA2 and high PRTN3 expression predicts poor survival in patients with pancreatic cancer.
Overexpression of hydroxyproline via EGLN/HIF1A is associated with distant metastasis in pancreatic cancer.
Systematic Analysis of the Expression and Prognostic Significance of P4HA1 in Pancreatic Cancer and Construction of a lncRNA-miRNA-P4HA1 Regulatory Axis.
Pancreatitis
Failure of a prolyl 4-hydroxylase inhibitor to alter extracellular matrix deposition during experimental pancreatitis.
Paraganglioma
PHD2 inactivation in Type I cells drives HIF-2?-dependent multilineage hyperplasia and the formation of paraganglioma-like carotid bodies.
Paraproteinemias
The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.
Periodontitis
An injectable hydrogel-formulated inhibitor of prolyl-4-hydroxylase promotes T regulatory cell recruitment and enhances alveolar bone regeneration during resolution of experimental periodontitis.
Pheochromocytoma
EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance.
Familial nonsyndromic pheochromocytoma.
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer.
Polycythemia
A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis.
A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove.
Biochemical characterization of human prolyl hydroxylase domain protein 2 variants associated with erythrocytosis.
Disturbance in the HIF-1alpha pathway associated with erythrocytosis: further evidences brought by frameshift and nonsense mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene.
Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury.
HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques.
Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene.
Notch Downregulation and Extramedullary Erythrocytosis in Hypoxia-Inducible Factor Prolyl 4-Hydroxylase 2-Deficient Mice.
Oxygen sensing: recent insights from idiopathic erythrocytosis.
Pre-Eclampsia
Study on the Expressions of PHD and HIF in Placentas from Normal Pregnant Women and Patients with Preeclampsia.
[Clinical significance of hypoxia inducible factor-prolyl hydroxylase 1 and factor inhibiting hypoxia inducible factor-1 expression in placentas of women with severe pre-eclampsia]
procollagen-proline 4-dioxygenase deficiency
Activation of hypoxia response in endothelial cells contributes to ischemic cardioprotection.
Haematopoietic prolyl hydroxylase-1 deficiency promotes M2 macrophage polarization and is both necessary and sufficient to protect against experimental colitis.
Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury.
HIF-P4H-2 deficiency protects against skeletal muscle ischemia-reperfusion injury.
Prostatic Neoplasms
Identification of P4HA1 as a prognostic biomarker for high-grade gliomas.
MicroRNA-1205, encoded on chromosome 8q24, targets EGLN3 to induce cell growth and contributes to risk of castration-resistant prostate cancer.
The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression.
Pulmonary Disease, Chronic Obstructive
Mining novel cell glycolysis related gene markers that can predict the survival of colon adenocarcinoma patients.
[The expression of hypoxia-inducible factor-1alpha and its hydroxylases in pulmonary arteries of patient with chronic obstructive pulmonary disease].
Pulmonary Fibrosis
Immunohistological detection of the beta subunit of prolyl 4-hydroxylase in rat and mini pig lungs with radiation-induced pulmonary fibrosis.
Peplomycin sulfate and pulmonary fibrosis: hydroxyproline, uronic acid, proline hydroxylase and glucosamine 6-phosphate synthetase in lungs of hamsters treated with peplomycin.
Protocollagen proline hydroxylase activity in experimental pulmonary fibrosis of rats.
Renal Insufficiency, Chronic
A 24-Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients.
A highly sensitive and selective UPLC-MS/MS assay for the determination of enarodustat (JTZ-951) in human plasma.
A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study.
A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
A phase 3, open-label, single-arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis-stimulating agents.
A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial.
Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone.
Anemia management in dialysis patients: a PIVOT and a new path?
Antianemia Drug Roxadustat (FG-4592) Protects Against Doxorubicin-Induced Cardiotoxicity by Targeting Antiapoptotic and Antioxidative Pathways.
Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review.
Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis.
Daprodustat: First Approval.
Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects.
Effect of the Phosphate Binders Sevelamer Carbonate and Calcium Acetate on the Pharmacokinetics of Roxadustat After Concomitant or Time-separated Administration in Healthy Individuals.
Effectiveness of hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat on renal anemia in non-dialysis-dependent chronic kidney disease: a systematic review and meta-analysis.
Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.
Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis.
Effects of oral iron and calcium supplement on the pharmacokinetics and pharmacodynamics of molidustat: an oral HIF-PH inhibitor for the treatment of renal anaemia.
Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents.
Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.
Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a systematic review and meta-analysis.
Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial.
Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD).
Erythropoietin regulates metabolic response in mice via receptor expression in adipose tissue, brain and bone.
Evaluation of Food and Spherical Carbon Adsorbent Effects on the Pharmacokinetics of Roxadustat in Healthy Nonelderly Adult Male Japanese Subjects.
Evaluation of the effect of lanthanum carbonate hydrate on the pharmacokinetics of roxadustat in non-elderly healthy adult male subjects.
Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.
Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Patients with Renal Anemia: A Meta-Analysis of Randomized Trials.
Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation.
In response to "Title: Letter to the Editor in response to the article 'Efficacy and safety of HIF prolyl hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis'".
Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study.
Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
Kidney pericyte hypoxia-inducible factor regulates erythropoiesis but not kidney fibrosis.
Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Novel Compound Induces Erythropoietin Secretion through Liver Effects in Chronic Kidney Disease Patients and Healthy Volunteers.
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD.
Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).
Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES).
Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS).
Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.
Two long-term phase 3 studies of enarodustat (JTZ-951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND-Long and HD-Long studies.
Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open-label study in Japan.
Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients.
[Future perspectives of treatment for anemia in chronic kidney disease (CKD) using hypoxia-inducible factor prolyl hydroxylase inhibitors].
Reperfusion Injury
HIF-P4H-2 deficiency protects against skeletal muscle ischemia-reperfusion injury.
Retinal Detachment
Prolyl-4-Hydroxylases Inhibitor Stabilizes HIF-1? and Increases Mitophagy to Reduce Cell Death After Experimental Retinal Detachment.
Retinal Diseases
Hypoxia-inducible factor expression in human RPE cells.
Retinal Neovascularization
REDUCED RETINAL NEOVASCULARIZATION, VASCULAR PERMEABILITY, AND APOPTOSIS IN ISCHEMIC RETINOPATHY IN THE ABSENCE OF PROLYL HYDROXYLASE-1 DUE TO THE PREVENTION OF HYPEROXIA-INDUCED VASCULAR OBLITERATION.
Sarcoma
Analysis of HIF-1alpha and its regulator, PHD2, in retroperitoneal sarcomas: Clinico-pathologic implications.
Appearance of collagen proline hydroxylase in sera of mice with implanted sarcomas.
Immunofluorescence localization of prolyl 4-hydroxylase isoenzymes and type I and II collagens in bone tumours: type I enzyme predominates in osteosarcomas and chondrosarcomas, whereas type II enzyme predominates in their benign counterparts.
Schistosomiasis mansoni
Elevation of laminin and beta-subunit of prolyl 4-hydroxylase in the sera of human subjects with Schistosomiasis mansoni.
Scleroderma, Systemic
Cytokine regulation of prolyl 4-hydroxylase production in skin fibroblast cultures from patients with systemic sclerosis: contribution to collagen synthesis and fibrosis.
Effect of prolyl 4-hydroxylase inhibitor on fibroblast collagen production in vitro: an approach to the treatment of systemic sclerosis.
Scurvy
Collagen proline hydroxylase in wound healing, granuloma formation, scurvy, and growth.
Sleep Apnea, Obstructive
Prolyl 4-Hydroxylase Domain Protein 3-Inhibited Smooth-Muscle-Cell Dedifferentiation Improves Cardiac Perivascular Fibrosis Induced by Obstructive Sleep Apnea.
Spinal Cord Injuries
Hypoxia-inducible factor prolyl hydroxylase domain (PHD) inhibition after contusive spinal cord injury does not improve locomotor recovery.
Squamous Cell Carcinoma of Head and Neck
High P4HA1 expression is an independent prognostic factor for poor overall survival and recurrent-free survival in head and neck squamous cell carcinoma.
Identification of PRDX4 and P4HA2 as Metastasis-Associated Proteins in Oral Cavity Squamous Cell Carcinoma by Comparative Tissue Proteomics of Microdissected Specimens Using iTRAQ Technology.
Overexpression and Nuclear Translocation of Hypoxia-Inducible Factor Prolyl Hydroxylase PHD2 in Head and Neck Squamous Cell Carcinoma Is Associated with Tumor Aggressiveness.
P4HA1: A single-gene surrogate of hypoxia signatures in oral squamous cell carcinoma patients.
Prognostic value of partial EMT-related genes in head and neck squamous cell carcinoma by a bioinformatic analysis.
Prolyl 4-hydroxylase subunit alpha 3 presents a cancer promotive function in head and neck squamous cell carcinoma via regulating epithelial-mesenchymal transition.
Stomach Neoplasms
Collagen biosynthesis in gastric cancer: immunohistochemical analysis of prolyl 4-hydroxylase.
Immunohistochemical study of collagen synthesis in an in-vitro model of scirrhous carcinoma of the stomach.
LncRNA PCGEM1 enhances metastasis and gastric cancer invasion through targeting of miR-129-5p to regulate P4HA2 expression.
P4HA3 is Epigenetically Activated by Slug in Gastric Cancer and its Deregulation is Associated With Enhanced Metastasis and Poor Survival.
Prognostic value of hypoxia-inducible factor-1 alpha and prolyl 4-hydroxylase beta polypeptide overexpression in gastric cancer.
Stomach Ulcer
Kinetics of fibroblasts in ulcer healing in rats: interference with indomethacin.
Stroke
Hypoxia-inducible factor prolyl hydroxylase inhibition: robust new target or another big bust for stroke therapeutics?
Reactive Oxygen Species Formation in the Brain at Different Oxygen Levels: The Role of Hypoxia Inducible Factors.
Teratocarcinoma
An increase in prolyl-4-hydroxylase activity occurs during the retinoic acid-induced differentiation of mouse teratocarcinoma stem cell lines F9 and P19.
Teratoma
VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo.
Thyroid Neoplasms
Fibrosis in undifferentiated (anaplastic) thyroid carcinomas: evidence for a dual action of tumour cells in collagen type I synthesis.
Triple Negative Breast Neoplasms
Prognostic and functional importance of the engraftment-associated genes in the patient-derived xenograft models of triple-negative breast cancers.
Tyrosinemias
Tyrosinemia I, a model for human diseases mediated by 2-oxoacid-utilizing dioxygenases: hepatotoxin suppression by NTBC does not normalize hepatic collagen metabolism.
Urinary Bladder Neck Obstruction
Collagen prolyl 4-hydroxylase is up-regulated in an acute bladder outlet obstruction.
Effects of Prolyl 4-Hydroxylase Inhibitor on Bladder Function, Bladder Hypertrophy and Collagen Subtypes in a Rat Model With Partial Bladder Outlet Obstruction.
Urinary Bladder Neoplasms
Targeted Inhibition of P4HB Promotes Cell Sensitivity to Gemcitabine in Urothelial Carcinoma of the Bladder.
Uterine Cervical Neoplasms
Collagen prolyl 4-hydroxylase 2 predicts worse prognosis and promotes glycolysis in cervical cancer.
Constructe a novel 5 hypoxia genes signature for cervical cancer.
P4HA2 contributes to cervical cancer progression via inducing epithelial-mesenchymal transition.
Vasculitis
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.
von Hippel-Lindau Disease
Liver hypoxia and lack of recovery after reperfusion at high blood alcohol levels in the intragastric feeding model of alcohol liver disease.